Blueprint Medicines Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for BLUEPRINT MEDICINES, and what generic alternatives to BLUEPRINT MEDICINES drugs are available?
BLUEPRINT MEDICINES has one approved drug.
There are three US patents protecting BLUEPRINT MEDICINES drugs.
There are forty patent family members on BLUEPRINT MEDICINES drugs in thirty-one countries and thirteen supplementary protection certificates in twelve countries.
Summary for Blueprint Medicines
| International Patents: | 40 |
| US Patents: | 3 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Blueprint Medicines
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blueprint Medicines | AYVAKIT | avapritinib | TABLET;ORAL | 212608-005 | Jun 16, 2021 | RX | Yes | No | 9,944,651 | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
| Blueprint Medicines | AYVAKIT | avapritinib | TABLET;ORAL | 212608-002 | Jan 9, 2020 | RX | Yes | No | 9,994,575 | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
| Blueprint Medicines | AYVAKIT | avapritinib | TABLET;ORAL | 212608-001 | Jan 9, 2020 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | |||||
| Blueprint Medicines | AYVAKIT | avapritinib | TABLET;ORAL | 212608-003 | Jan 9, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | |||||
| Blueprint Medicines | AYVAKIT | avapritinib | TABLET;ORAL | 212608-002 | Jan 9, 2020 | RX | Yes | No | 9,944,651 | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Blueprint Medicines Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 110003217 | See Plans and Pricing |
| Japan | 2019048878 | See Plans and Pricing |
| Hungary | E059041 | See Plans and Pricing |
| Singapore | 11201602937U | See Plans and Pricing |
| Poland | 3409674 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Blueprint Medicines Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3057969 | C202130012 | Spain | See Plans and Pricing | PRODUCT NAME: AVAPRITINIB Y SALES FARMACEUTICAMENTE ACEPTABLES DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/20/1473; DATE OF AUTHORISATION: 20200924; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1473; DATE OF FIRST AUTHORISATION IN EEA: 20200924 |
| 3057969 | 2021C/509 | Belgium | See Plans and Pricing | PRODUCT NAME: AVAPRITINIB ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/20/1473 20200925 |
| 3057969 | PA2021003 | Lithuania | See Plans and Pricing | PRODUCT NAME: AVAPRITINIBAS IR JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS; REGISTRATION NO/DATE: EU/1/20/1473 20200924 |
| 3057969 | 132021000000035 | Italy | See Plans and Pricing | PRODUCT NAME: AVAPRITINIB E SUOI SALI FARMACEUTICAMENTE ACCETTABILI(AYVAKYT); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1473, 20200925 |
| 3057969 | 122021000014 | Germany | See Plans and Pricing | PRODUCT NAME: AVAPRITINIB UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; REGISTRATION NO/DATE: EU/1/20/1473 20200924 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
